

Table of Contents

List of Abbreviations and Acronyms	iii
Interagency Coordinating Committee on the Validation of Alternative Methods: Agency Representatives.....	v
Acknowledgements	vii
Preface.....	xiii
Executive Summary	xvii
1.0 Purpose and Background of Performance Standards.....	1
1.1 Introduction.....	1
1.2 Elements of ICCVAM Performance Standards	2
1.3 ICCVAM Process for the Development of LLNA Performance Standards	2
1.4 ICCVAM Development of a Performance Standard for the LLNA	3
1.4.1 Background on Skin Sensitization	3
1.4.2 Test Methods for Assessing Skin Sensitization	4
1.4.3 Intended Regulatory Uses for the LLNA	4
1.4.4 Similarities and Differences in the Endpoints of the LLNA and Reference Skin Sensitization Test Methods	4
2.0 LLNA Performance Standards.....	7
2.1 Background.....	7
2.2 LLNA Essential Test Method Components and Other Validation Considerations.....	7
2.2.1 Essential Test Method Components.....	7
2.2.2 Other Validation Considerations.....	8
2.2.3 LLNA Test Method Protocol Modifications.....	9
2.2.4 Data and Reporting	10
2.3 Minimum List of Reference Substances for Methods Assessing Lymphocyte Proliferation	12
2.3.1 Criteria for Selection of Reference Substances	12
2.3.2 Characteristics of Selected Reference Substances	12
2.4 Accuracy and Reliability Performance Values	13
2.4.1 Accuracy	13

2.4.2	Reliability.....	14
3.0	References.....	17
Appendix A	ICCVAM-Recommended Test Method Protocol (Updated 2008): The Murine Local Lymph Node Assay	A-1
	Annex I: An Approach to Dissection and Identification of the Draining ("Auricular") Lymph Nodes	A-15
	Annex II: An Example of How to Reduce the Number of Animals in the Concurrent Positive Control Group of the Local Lymph Node Assay	A-19
	Annex III: Evaluating Local Irritation and Systemic Toxicity in the Local Lymph Node Assay	A-21
Appendix B	Evaluating the Impact of Reducing the Sample Size from Five to Four Animals per Group on the Performance of the Ratio Rule of SI > 3 in LLNA Testing	B-1
	Annex I: Summary of Study Results – CBA Mouse Database.....	B-15
Appendix C	Essential Test Method Components and Other Validation Considerations for the Murine Local Lymph Node Assay.....	C-1
Appendix D	Timeline for Development of the ICCVAM Murine Local Lymph Node Assay Performance Standards.....	D-1
Appendix E	Supporting Documents: Development of the ICCVAM LLNA Performance Standards.....	E-1
	E1 Methods Applicable to the ICCVAM LLNA Performance Standards and Essential Test Method Components.....	E-3
	E2 Selection of Proposed Performance Standards Reference Substances .	E-9
	E3 Rationale for the Required Accuracy and Reliability Statistics Included in the Test Method Performance Evaluation	E-25
Appendix F	ICCVAM LLNA Performance Standards: Recommended Reference Substances.....	F-1
	F1 Recommended Reference Substances – Alphabetically Sorted.....	F-3
	F2 Recommended Reference Substances – Structures and Product Uses .	F-7
	F3 Recommended Reference Substances – Murine Local Lymph Node Assay Data	F-15